May 27 (Reuters) - Australia's drug regulator said on Wednesday it was notified by biopharmaceutical giant CSL's unit Seqirus that it will be discontinuing all strengths of their Benpen injection ...

After a brutal year for CSL shares, insider buying is starting to attract market attention. Here's the details.

May 27 (Reuters) - The vaccine arm of Australian biopharmaceutical giant CSL said on Wednesday it will discontinue sales of an injectable medicine used to treat bacterial infections, citing the ...

The global biotechnology company will brief analysts on its latest downgrade on Monday morning after a horror year for the business.

CSL ( (AU:CSL)) has shared an announcement. CSL Limited has provided an updated daily notification on its ongoing on-market share buy-back of ordinary fully paid shares, originally launched in August ...

Having flagged modest revenue and earnings growth for the full year, CSL now has warned it will go backwards on both metrics.

Let’s dig into the relative performance of Carlisle (NYSE:CSL) and its peers as we unravel the now-completed Q1 building ...

After an antitrust review knocked 2021’s biggest biopharma buyout off course in May, CSL’s $11.7 billion deal for Swiss iron deficiency specialist Vifor Pharma appears to be back on track. Tuesday, ...

Amid uncertainty for its vaccine division, CSL is growing the footprint of its bread-and-butter plasma therapies business by pledging a capital investment of about $1.5 billion for U.S.-based ...